Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01192165
First received: August 30, 2010
Last updated: November 21, 2013
Last verified: November 2013
  Purpose

The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, erlotinib, pemetrexed, pemetrexed + carboplatin, pemetrexed + cisplatin, or nab-paclitaxel). The doses identified in this study may be used in future trials to test whether the combination treatment is a safe and effective therapy for subjects with metastatic lung and/or pancreatic cancers.


Condition Intervention Phase
Cancer
Drug: Trametinib (GSK1120212)
Drug: Docetaxel
Drug: Erlotinib
Drug: Pemetrexed
Drug: Carboplatin
Drug: nab-Paclitaxel
Drug: Cisplatin
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination [ Time Frame: Duration of study (approximately 3 years) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To characterize population pharmacokinetic parameters [ Time Frame: Duration of study (approximately 3 years) ] [ Designated as safety issue: Yes ]
  • To evaluate the anti-tumor activity as assessed by tumor response rate according to RECIST v1.1 [ Time Frame: Duration of study (approximately 3 years) ] [ Designated as safety issue: No ]

Enrollment: 169
Study Start Date: September 2010
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Group 1
Trametinib plus Docetaxel
Drug: Trametinib (GSK1120212)
Investigational small molecule targeted therapy (MEK1/2 inhibitor)
Drug: Docetaxel
Chemotherapy
Experimental: Treatment Group 2
Trametinib plus Erlotinib
Drug: Trametinib (GSK1120212)
Investigational small molecule targeted therapy (MEK1/2 inhibitor)
Drug: Erlotinib
Small molecule targeted therapy (EGFR inhibitor)
Experimental: Treatment Group 3
Trametinib plus Pemetrexed
Drug: Trametinib (GSK1120212)
Investigational small molecule targeted therapy (MEK1/2 inhibitor)
Drug: Pemetrexed
Chemotherapy
Experimental: Treatment Group 4
Trametinib plus Pemetrexed and Carboplatin
Drug: Trametinib (GSK1120212)
Investigational small molecule targeted therapy (MEK1/2 inhibitor)
Drug: Pemetrexed
Chemotherapy
Drug: Carboplatin
Chemotherapy
Experimental: Treatment Group 5
Trametinib plus nab-Paclitaxel
Drug: Trametinib (GSK1120212)
Investigational small molecule targeted therapy (MEK1/2 inhibitor)
Drug: nab-Paclitaxel
Chemotherapy
Experimental: Treatment Group 6
Trametinib plus Pemetrexed and Cisplatin
Drug: Trametinib (GSK1120212)
Investigational small molecule targeted therapy (MEK1/2 inhibitor)
Drug: Pemetrexed
Chemotherapy
Drug: Cisplatin
Chemotherapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation.
  • Tumor progression following at least one prior standard therapy, the subject refuses standard therapy, or no standard therapy exists.
  • The subject has a radiographically measurable tumor.
  • The subject is able to carry out daily life activities without difficulty.
  • The subject is able to swallow and retain oral medication.
  • The subject does not have significant side effects from previous anti-cancer treatment.
  • The subject has adequate organ and blood cell counts.
  • Sexually active subjects must use medically acceptable methods of contraception during the course of the study.

Exclusion Criteria:

  • The subject has had major surgery or received certain types of cancer therapy within 2-3 weeks before starting the study.
  • The subject has a brain tumor.
  • Current severe, uncontrolled systemic disease.
  • History of clinically significant heart, lung, or eye/vision problems.
  • The subject has high blood pressure that is not well-controlled with medication.
  • The subject has a permanent pacemaker.
  • The subject is pregnant or breastfeeding.
  • Positive for Hepatitis B, Hepatitis C, or HIV.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01192165

Locations
United States, Arizona
GSK Investigational Site
Scottsdale, Arizona, United States, 85259
United States, California
GSK Investigational Site
Duarte, California, United States, 91010
GSK Investigational Site
Sacramento, California, United States, 95817
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80218
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89169
United States, New York
GSK Investigational Site
Albany, New York, United States, 12206
United States, South Carolina
GSK Investigational Site
Greenville, South Carolina, United States, 29605
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75246
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
Tyler, Texas, United States, 75702
United States, Virginia
GSK Investigational Site
Norfolk, Virginia, United States, 23502
United States, Washington
GSK Investigational Site
Vancouver, Washington, United States, 98684
Canada, Ontario
GSK Investigational Site
Toronto, Ontario, Canada, M5G 2M9
France
GSK Investigational Site
Caen Cedex 9, France, 14033
GSK Investigational Site
Marseille cedex 5, France, 13385
GSK Investigational Site
Saint-Herblain cedex, France, 44805
GSK Investigational Site
Toulouse cedex, France, 31052
Korea, Republic of
GSK Investigational Site
Seoul, Korea, Republic of, 120-752
GSK Investigational Site
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01192165     History of Changes
Other Study ID Numbers: 113486, 2012-000257-32
Study First Received: August 30, 2010
Last Updated: November 21, 2013
Health Authority: European Union: European Medicines Agency
Korea: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by GlaxoSmithKline:
Taxotere
Cisplatin
Carboplatin
Trametinib
GSK1120212
Tarceva
KRAS
Pemetrexed
MEK inhibitor
nab-Paclitaxel
Docetaxel
Alimta
Abraxane
Erlotinib

Additional relevant MeSH terms:
Carboplatin
Cisplatin
Docetaxel
Erlotinib
Paclitaxel
Pemetrexed
Trametinib
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Folic Acid Antagonists
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 25, 2014